KAV03501
Anti-Rabies Virus (RABV) Glycoprotein (G) Human IgG Antibody
Colorimetric
Plasma, Serum
Quantitative
1.56 - 100 ng/mL
1.09 ng/mL
CV<15%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Development of an oral gut-targeted rabies virus-like particles (RVLPs) vaccine with mucosal immune adjuvant LTB via delivering of localized-release microparticles., PMID:40476513
Analysis of the antigenic and immunogenic properties of the native rabies virus glycoprotein purified by Lens culinaris lectin affinity chromatography., PMID:39413880
A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice., PMID:39129566
Fc engineered anti-virus therapeutic human IgG1 expressed in plants with altered binding to the neonatal Fc receptor., PMID:38528347
A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity., PMID:38262810
Development and Evaluation of an Enzyme-Linked Immunosorbent Assay Targeting Rabies-Specific IgM and IgG in Human Sera., PMID:37112853
The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency., PMID:34896446
An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens., PMID:34086672
Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice., PMID:33985418
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial., PMID:33487468
Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA., PMID:33352107
Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor., PMID:32321812
Immune responses in mice and pigs after oral vaccination with rabies virus vectored Nipah disease vaccines., PMID:31928698
Novel strategy for expression and characterization of rabies virus glycoprotein., PMID:31904423
An ELISA-based method for detection of rabies virus nucleoprotein-specific antibodies in human antemortem samples., PMID:30403742
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever., PMID:30310067
[A DNA Construct That Encodes the Rabies Virus Consensus Glycoprotein with a Proteasome Degradation Signal Induces Antibody Production with IgG2A Subtype Predominance]., PMID:29989585
Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs., PMID:28822816
APRIL:TACI axis is dispensable for the immune response to rabies vaccination., PMID:28619678
Engineering of a novel zipFv using leucine zipper motif against rabies virus glycoprotein G with improved protection potency in vivo., PMID:28389318
[Generation of Human ScFv Antibodies for Antigenic Site III of Rabies Virus Glycoprotein from Antibody-phage Libraries by Chain Shuffling]., PMID:29979522
A novel variable antibody fragment dimerized by leucine zippers with enhanced neutralizing potency against rabies virus G protein compared to its corresponding single-chain variable antibody fragment., PMID:26325475
Identification of rabies virus mimotopes screened from a phage display peptide library with purified dog anti-rabies virus serum IgG., PMID:23499997
Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein., PMID:22678022
Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge., PMID:21549784
[The development of neutralizing human antibodies against rabies virus]., PMID:20836379
Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice., PMID:19741168
Peptide mimotopes of rabies virus glycoprotein with immunogenic activity., PMID:19520204
An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies., PMID:19429758
Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein., PMID:19081687
[The influence of the FR-1 in heavy chain (VH) of antibodies on antibody secretion]., PMID:18683552
Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies., PMID:17637573
Further studies on the mechanism of rabies virus neutralization by a viral glycoprotein-specific monoclonal antibody, #1-46-12., PMID:16113501
The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries., PMID:15971273
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein., PMID:15031791
T helper cell-independent antibody responses to the transgene product of an e1-deleted adenoviral vaccine require NK1.1 T cells., PMID:12573585
Mutations conferring resistance to neutralization by a soluble form of the neurotrophin receptor (p75NTR) map outside of the known antigenic sites of the rabies virus glycoprotein., PMID:12368318
Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice., PMID:9627012
Antigen-specific immune responses in cattle with inherited beta2-integrin deficiency., PMID:9343338
Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity., PMID:7877965
Modulation of antiviral immune responses by exogenous cytokines: effects of tumour necrosis factor-alpha, interleukin-1 alpha, interleukin-2 and interferon-gamma on the immunogenicity of an inactivated rabies vaccine., PMID:8113740
Mechanisms of rabies virus neutralization., PMID:7683158
Generation of human monoclonal antibodies by transformation of lymphoblastoid B cells with ras oncogene., PMID:8450236
Clonal analysis of a human antibody response. II. Sequences of the VH genes of human IgM, IgG, and IgA to rabies virus reveal preferential utilization of VHIII segments and somatic hypermutation., PMID:8432980
Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection., PMID:8352659
Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera., PMID:2613705
Production of monoclonal antibodies against the Pasteur (P.V.) strain of rabies virus: problems and results., PMID:6526139
The advantage and adequacy of the mixed hemadsorption test for rabies antibody determination., PMID:355017
[Rabies anti-glycoprotein IgG conjugated with peroxidase and fluorescein isothiocyanate (author's transl)]., PMID:1108733
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
